Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Cancer shared this article with you from Inoreader Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer Via MedWorm Cancer & Oncology Clinical Trials Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Metastatic Lung Non-Small Cell Carcinoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Triple-Negative Breast Carcinoma;   Metastatic Urothelial Carcinoma;   Prognostic Stage IV Breast Cancer AJCC v8;   Stage IV Lu ng Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8 Interventions:   Drug: Atezolizumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells;   Biological: PD1 Inhibitor Sponsors:   Fred Hutchinson Cancer Research Center;   SignalOne Bio, Inc. Not yet recruiting (Source: Clinica lTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.